Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Biocatalyst product sales	$ 3,740	$ 3,076
Biocatalyst research and development	3,534	2,197
Revenue sharing arrangement	722	1,525
Total revenues	7,996	6,798
Costs and operating expenses:
Cost of biocatalyst product sales	2,489	1,456
Research and development	5,686	5,293
Selling, general and administrative	6,802	5,578
Total costs and operating expenses	14,977	12,327
Loss from operations	(6,981)	(5,529)
Interest income	15	4
Other income (expense)	3	(25)
Loss before income taxes	(6,963)	(5,550)
Provision for income taxes	11	12
Net loss	$ (6,974)	$ (5,562)
Net loss per share, basic and diluted (usd per share)	$ (0.17)	$ (0.14)
Weighted average common shares used in computing net loss per share, basic and diluted (shares)	40,072	38,779